White House Press Secretary Karoline Leavitt told reporters that President Trump would be implementing tariffs on Canada, ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...